Overall, major, and VGPR/CR responses for 135 WM patients with sporadic (A) or familial (B) disease who received either bortezomib or a non-bortezomib containing regimen. *p=0.05; and **p=0.0006 among familial WM patients who received bortezomib versus non-bortezomib containing therapy.